PharmaEssentia Corporation: New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022
Presentations to illustrate long-term results from the PROUD/CONTINUATION studies as well as new insights on ropeginterferon alfa-2b in polycythemia vera (PV) patients in Japan PharmaEssentia Corp… FinanzNachrichten.de: Meistgelesene Nachrichten
